Terry McGuire is a co-founder and general partner of Polaris Venture Partners, a venture capital firm with over 90 companies and over $3.0 billion in invested capital. Polaris focuses its early stage investing on companies in the life sciences and information technology areas.
Prior to starting Polaris, Mr. McGuire spent seven years at Burr, Egan, Deleage & Co. investing in early stage medical and information technology companies. Mr. McGuire began his career in venture capital at Golder, Thoma and Cressey in Chicago.
Mr. McGuire has co-founded three companies: Inspire Pharmaceuticals, AIR (Advanced Inhalation Research, Inc.), and MicroCHIPS. Currently, Mr. McGuire represents Polaris on the boards of directors of Acceleron Pharma, Adimab, Arsenal Medical, Inc., Cerulean Pharma Inc., Ironwood Pharmaceuticals, Life Line Screening, MicroCHIPS, Inc., Pulmatrix Inc., and Trevena Inc. He has also served on the boards of Akamai, Aspect Medical Systems, Cubist Pharmaceuticals, deCODE Genetics, GlycoFi, Transform Pharmaceuticals, and Remon Medical Technologies.
Mr. McGuire is currently Chairman of the National Venture Capital Association, which represents ninety percent of the venture capitalists in the United States. Mr. McGuire also serves on the boards of the Thayer School of Engineering, Dartmouth College (Chair), MIT’s The David H. Koch Institute for Integrative Cancer Research, and The Arthur Rock Center for Entrepreneurship at HBS.
Mr. McGuire received a MBA from Harvard Business School, a MS in engineering from The Thayer School at Dartmouth College and a BS in physics and economics from Hobart College.
Mr. McGuire is a recipient of the Albert Einstein Award for Outstanding Achievement in the Life Sciences, awarded by Forbes/Gottlieb Medical Technology Investor, Harvard MIT Biomedical Engineering Center, the New Jerusalem Foundation, the Jerusalem Development Authority, and Rodman and Renshaw.